http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2759469-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9c395ad85c83717de84346aeb2e8552 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-493 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-493 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-70 |
| filingDate | 2021-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c36d3232981c93f789d9697330e884ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_846dbf568969528e8dc93a7f8dfc37b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_134fafb5847f8d6b5c1f11edc18a4e47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bd48d78f9dd0d5e5b60f95cd781398c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c93a4776e3888c9ca252ca443a6322c |
| publicationDate | 2021-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2759469-C1 |
| titleOfInvention | Method for monitoring the effectiveness of antibiotic therapy in the treatment of acute pyelonephritis in infants |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to pediatrics and pediatric nephrology, and can be used to monitor the effectiveness of antibiotic therapy in the treatment of acute pyelonephritis in infants. A portion of urine is collected in a volume of 5 ml after the toilet of the genitals, before starting antibiotic therapy, with the determination in the urine of the initial level of Lipocalin-2 associated with neutrophilic gelatinase (uNGAL), and its standardization by conversion to mg of creatinine (uNGAL/Cr) in this portions of urine, with its repeated determination on the 2nd day of antibiotic therapy. If the uNGAL/Cr level decreases by 50% or less from the uNGAL/Cr level established before the start of antibiotic therapy, it is considered ineffective and a decision is made to change the antibiotic. In the case of a decrease of more than 50% from the initial level, continue the course of treatment with the same antibacterial drug until the uNGAL/Cr level decreases to 2.0 ng/mg or lower. n EFFECT: method provides an opportunity to obtain reliable information about the dynamics of the course of acute pyelonephritis in infants against the background of ongoing antibiotic therapy due to the implementation of a non-invasive method of monitoring the effectiveness of antibiotic therapy, which consists in determining in the urine the initial level of Lipocalin-2 associated with uNGAL before starting antibiotic therapy and 2- e day, and comparison of indicators, which provides an earlier accurate assessment of the effectiveness of antibiotic therapy and, in case of ineffectiveness, an early change of an ineffective antibacterial drug. n 1 cl, 1 dwg, 1 tbl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2761738-C1 |
| priorityDate | 2021-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.